Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Dietlein

Showing results (41-50 of 141) with videos related to

Pageof 15
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|November 30, 2002
Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomasMatthias Schmidt, Eva Fischer, Markus Dietlein, et al.
Molecular Imaging and Biology|February 28, 2016
Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617Melanie Hohberg, Wolfgang Eschner, Matthias Schmidt, et al.
Journal of Thoracic Disease|January 22, 2016
Developments in oncological positron emission tomography/computed tomography assessmentCarsten Kobe, Ronald Boellaard, Jürgen Wolf, et al.
Thyroid : Official Journal of the American Thyroid Association|March 31, 2006
Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid diseaseMatthias Schmidt, Eva Gorbauch, Markus Dietlein, et al.
Nuclear Medicine Communications|November 13, 2009
Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?Carsten Kobe, Wolfgang Eschner, Markus Wild, et al.
The Annals of Otology, Rhinology, and Laryngology|December 24, 2008
Is there a need for positron emission tomography imaging to stage the N0 neck in T1-T2 squamous cell carcinoma of the oral cavity or oropharynx?Ursula Schroeder, Markus Dietlein, Claus Wittekindt, et al.
Nuklearmedizin. Nuclear Medicine|March 28, 2009
[Should all patients with thyroid nodules > or = 1 cm undergo fine-needle aspiration biopsy?]Harald Schicha, M Hellmich, W Lehmacher, et al.
Expert Review of Anticancer Therapy|September 15, 2010
The role of PET in Hodgkin's lymphoma and its impact on radiation oncologyCarsten Kobe, Markus Dietlein, Jan Kriz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 2012
Recombinant human TSH versus thyroid hormone withdrawalFrederik A Verburg, Markus Dietlein, Lutz Freudenberg, et al.
Nuclear Medicine Communications|November 22, 2018
Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma: is it significantly affected by contrast-enhanced computed tomography attenuation correction?Conrad-Amadeus Voltin, Jasmin Mettler, Ronald Boellaard, et al.
Pageof 15

Showing results (41-50 of 141) with videos related to

Sort By:
Pageof 15
European Journal of Nuclear Medicine and Molecular Imaging|November 30, 2002
Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomasMatthias Schmidt, Eva Fischer, Markus Dietlein, et al.
Molecular Imaging and Biology|February 28, 2016
Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617Melanie Hohberg, Wolfgang Eschner, Matthias Schmidt, et al.
Journal of Thoracic Disease|January 22, 2016
Developments in oncological positron emission tomography/computed tomography assessmentCarsten Kobe, Ronald Boellaard, Jürgen Wolf, et al.
Thyroid : Official Journal of the American Thyroid Association|March 31, 2006
Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid diseaseMatthias Schmidt, Eva Gorbauch, Markus Dietlein, et al.
Nuclear Medicine Communications|November 13, 2009
Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?Carsten Kobe, Wolfgang Eschner, Markus Wild, et al.
The Annals of Otology, Rhinology, and Laryngology|December 24, 2008
Is there a need for positron emission tomography imaging to stage the N0 neck in T1-T2 squamous cell carcinoma of the oral cavity or oropharynx?Ursula Schroeder, Markus Dietlein, Claus Wittekindt, et al.
Nuklearmedizin. Nuclear Medicine|March 28, 2009
[Should all patients with thyroid nodules > or = 1 cm undergo fine-needle aspiration biopsy?]Harald Schicha, M Hellmich, W Lehmacher, et al.
Expert Review of Anticancer Therapy|September 15, 2010
The role of PET in Hodgkin's lymphoma and its impact on radiation oncologyCarsten Kobe, Markus Dietlein, Jan Kriz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 2012
Recombinant human TSH versus thyroid hormone withdrawalFrederik A Verburg, Markus Dietlein, Lutz Freudenberg, et al.
Nuclear Medicine Communications|November 22, 2018
Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma: is it significantly affected by contrast-enhanced computed tomography attenuation correction?Conrad-Amadeus Voltin, Jasmin Mettler, Ronald Boellaard, et al.
Pageof 15